Pure Global

BECTON DICKINSON DE COLOMBIA LTDA. - Authorized Company ProfileBECTON DICKINSON DE COLOMBIA LTDA.

Explore comprehensive authorized company profile for BECTON DICKINSON DE COLOMBIA LTDA. through Pure Global AI's free Colombia medical device database. This company manufactures 622 medical devices registered with INVIMA across 6 risk classes. Their registration history spans from Mar 07, 2022 to May 07, 2034.

This page provides detailed insights including recent registrations, risk class distribution (II: 251, I: 131, Unspecified: 106, and more), and complete regulatory information from the official Colombia INVIMA medical device database with bilingual Spanish/English support. Pure Global AI offers free access to Colombia's complete medical device registry.

Free Authorized Company Profile
Powered by Pure Global AI
622 Devices
6 Risk Classes
BECTON DICKINSON DE COLOMBIA LTDA.
BECTON DICKINSON DE COLOMBIA LTDA.
Authorized Company
622
Total Devices
6
Risk Classes
2022
Earliest
2034
Latest
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Recent Registrations
Latest 20 INVIMA device registrations

SISTEMA DE PREPARACIร“N DE MUESTRAS

SAMPLE PREPARATION SYSTEM

51332cb21abed82c895084bf06507ae0

I

INFINICYTโ„ข ADVANCED CE-IVD

INFINICYTโ„ข ADVANCED CE-IVD

10464984e5a9b380fbf3f6e4b70fd729

IIa

BD BBLโ„ข MACCONKEY II AGAR WITH SORBITOL

BD BBLโ„ข MACCONKEY II AGAR WITH SORBITOL

908211f74680450b11a40a83d354d42b

1. CD10-APC-C750

1. CD10-APC-C750

d21f74bad466d32280df9016549ba408

II
May 07, 2034

PE-CYโ„ข7 MOUSE ANTI-HUMAN CD31

PE-CYโ„ข7 MOUSE ANTI-HUMAN CD31

b796a770a8251cd48d2cd8d8bdf38c82

I
Apr 22, 2034

CD16-FITC / CD64-PE / CD45-PERCP-CYANINE5.5 / CD14-APC

CD16-FITC / CD64-PE / CD45-PERCP-CYANINE5.5 / CD14-APC

cdaa0c98e09e4734bbd651ad676b2e19

I
Apr 22, 2034

TCR-C?1-PE-CYANINE7

TCR-C?1-PE-CYANINE7

d8c5360a0db00933504e6c2c65624ffa

I
Apr 22, 2034

CD38-APC-C750

CD38-APC-C750

1408718df6f960d70b0a90227a774116

I
Apr 22, 2034

NG2-PE

NG2-OR

ccec72cd08646871ab95846f9a52929e

I
Apr 22, 2034

CD45-APC-C750โ„ข

CD45-APC-C750โ„ข

2025eb128c32867c87f190059cad054c

I
Apr 22, 2034

CD45-OC515โ„ข

CD45-OC515โ„ข

86671c0a79bb3917725e2073b8760fb8

I
Apr 22, 2034

CD56-PE

CD56-PE

444749eaba26ab6fc2a2ac7c88b30f25

I
Apr 22, 2034

CD59-FITC

CD59-FITC

869d56795e7122c67503e232951fd155

I
Apr 22, 2034

CD59-PE

CD59-PE

c85f0e90723f856491bd85289a7d7bd5

I
Apr 22, 2034

CYMPO-FITC

CYMPO-FITC

539c2aff5e9b8fadf26fe97e8efaea05

I
Apr 22, 2034

CD36-FITC

CD36-FITC

089462a55e6900c229e12f199c1ad10d

I
Apr 22, 2034

CD81-APC-C750โ„ข

CD81-APC-C750โ„ข

e214c41ab358d183d9f11d1aa96de81e

I
Apr 22, 2034

CYTOKERATIN 18-FITC

CYTOKERATIN 18-FITC

aace0b69267842ff3363cb1d2057296f

I
Apr 22, 2034

FITC MOUSE ANTI-HUMAN CD90

FITC MOUSE ANTI-HUMAN CD90

3100003e274b17daf34d639ef838297b

I
Apr 22, 2034

CD7-APC

CD7-APC

521ddc0905cf2efdad7d2b758534bcd0

I
Apr 22, 2034
Risk Class Distribution
Devices by risk class
II
251
40.4% of total
I
131
21.1% of total
Unspecified
106
17.0% of total
IIa
84
13.5% of total
III
27
4.3% of total
IIb
23
3.7% of total